New offering creates a connected path from product sample to prescription fulfilment, helping simplify access to RYALTRIS® for providers and patients
LAKEWOOD, N.J., Sept. 17, 2026 /PRNewswire-PRWeb/ -- CareTria, a leading provider of patient access, pharmacy, and commercialization solutions for the life sciences industry, today announced the launch of 'RYALTRIS® Direct, Powered by CareTria', a participating pharmacy offering from Eagle Pharmacy, LLC ("Eagle Pharmacy"), for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg*. The program combines Eagle Pharmacy's fulfillment capabilities with CareTria's engagement, telesales and sampling services to create a seamless pathway from product sampling through prescription fulfilment.
Through RYALTRIS® Direct, Eagle Pharmacy serves as the participating pharmacy for RYALTRIS® fulfillment. CareTria's telesales team supports provider outreach and education while managing a comprehensive sampling program, including HCP-initiated requests, e-sampling, and physician-administered distribution, enabling healthcare providers to have reliable access to product samples. By bringing these services together within a single coordinated program, RYALTRIS® Direct is designed to reduce the administrative complexity, accelerate therapy initiation and improve the overall experience for healthcare providers and patients.
"Manufacturers need more than a pharmacy partner — they need a connected system that spans sampling, patient initiation, and fulfillment," said Matt Wolf, Chief Commercial Officer at CareTria. "RYALTRIS® Direct reflects how we think about commercialization: as one continuous workflow, not a series of handoffs."
"RYALTRIS® Direct represents another important step in Glenmark's commitment to improving access to innovative respiratory therapies", said Marc Kikuchi, President & Business Head, North America at Glenmark Pharmaceuticals. " By bringing together provider support, product sampling and pharmacy fulfillment through a coordinated program, we are simplifying the path from prescription to treatment while advancing our patient-centric commercialization strategy in the U.S. Partnerships like this enable us to better support healthcare professionals and improve the treatment experience for patients prescribed RYALTRIS®."
RYALTRIS® is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older1. It is a fixed-dose combination nasal spray that combines olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) in a single formulation, offering a differentiated treatment option for patients with seasonal allergic rhinitis.
RYALTRIS® Direct is available now to providers and patients seeking access to RYALTRIS®. Patients with existing RYALTRIS® prescriptions may request that their prescription be transferred to Eagle Pharmacy, the dispensing pharmacy for RYALTRIS® Direct, Powered by CareTria.
*Calculated on the anhydrous basis
1RYALTRIS® Nasal Spray approved prescribing information, Glenmark Specialty SA, Switzerland.
Please click here to view full prescribing information, including Important Safety Information.
For additional information about RYALTRIS® and how to access, please visit us.ryaltris.com.
RYALTRIS is a registered trademark of Glenmark Specialty SA.
About CareTria
CareTria is a leading therapy initiation partner that helps pharma companies accelerate patient conversions and optimize gross-to-net through a faster path from order to therapy. Its exclusive provider network with embedded automated digital enrollment, including 85% of benefit investigations completed in under 60 seconds, connected to multi-modal fulfillment – including specialty pharmacy, direct-to-patient cash, samples, free-goods, and 3PL distribution – ensures a faster path from order to therapy. Real-time data and analytics drive continuous optimization across the product journey. By combining speed, precision, and scale, CareTria helps patients start therapy sooner while delivering measurable impact for its pharma partners. Learn more at www.caretria.com.
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com
Contacts For media inquiries, please contact: Lori Wood at [email protected].
Media Contact
Lori Wood, CareTria, 1 888-564-7737, [email protected], www.caretria.com
SOURCE CareTria
Share this article